Seagen and Astellas Report P-III Trial (EV-302) Results of Padcev (enfortumab vedotin-ejfv) and Keytruda for Advanced Bladder Cancer
Shots:
- The P-III trial (EV-302/KEYNOTE-A39) evaluating enfortumab vedotin + pembrolizumab vs CT in patients with previously untreated LA/mUC who were eligible for cisplatin- or carboplatin-containing CT regardless of PD-L1 status
- The study met its dual 1EPs of OS and PFS while an IDMC determined that OS crossed the pre-specified efficacy boundary at interim analysis. The safety results were consistent with those of enfortumab vedotin + pembrolizumab
- Padcev + Keytruda received accelerated approval from the US FDA in April 2023 for adult patients with la/mUC who are not eligible to receive cisplatin-containing CT, based on the (EV-103) trial results
Ref: Businesswire | Image: Seagen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
